LEXINGTON, Mass., Feb. 20, 2020 /PRNewswire/ -- Agenus Inc.
(NASDAQ: AGEN), an immuno-oncology company with an extensive
pipeline of agents designed to activate immune response to cancers,
today announced new clinical data from pre-planned interim analyses
of balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4) and data
from a dose escalation study of AGEN1181, a novel multi-functional
enhanced CTLA-4 antibody.
The interim analysis from 34 evaluable patients treated with the
combination of balstilimab (anti-PD-1) and zalifrelimab
(anti-CTLA-4) demonstrated a 20.6% overall response rate (ORR),
which included a complete response (CR) rate of 8.8% in second-line
cervical cancer. The interim analysis from 44 evaluable patients
treated with balstilimab monotherapy demonstrated an ORR of
11.4% in second-line cervical cancer. The clinical activity
observed in both studies are comparable to other agents in these
therapeutic classes. Both balstilimab monotherapy and the
combination of balstilimab and zalifrelimab were
well-tolerated with no new safety signals.
Additionally, early clinical data from a dose-escalation study
of AGEN1181 revealed a confirmed CR in a patient with a
difficult-to-treat, PD-L1 negative, microsatellite stable,
endometrial cancer. The patient was treated with a low dose of
AGEN1181 (1 mg/kg) and had failed prior treatment with a PD-1
inhibitor. Additionally, stable disease was noted in the majority
of patients treated. AGEN1181 monotherapy was well-tolerated.
Balstilimab, zalifrelimab and AGEN1181 are investigational agents
that have not been approved for any uses. Efficacy and safety have
not been established.
Details for today's Investor Day:
Date:
|
Thursday, February
20, 2020
|
Time:
|
9:00 –
11:00AM
|
Location:
|
New York,
NY (by invitation only)
|
Link to Webcast
Presenters will include global experts in immune-oncology, Dr.
Chuck Drake, Co-Director, Cancer
Immunotherapy Program, Columbia
University Herbert Irving Comprehensive Cancer Center, and
Dr. Bradley Monk, M.D., FACS, FACOG,
Co‐Director of GOG Partners, Arizona Oncology (US Oncology Network)
and Professor, Gynecologic Oncology at University of Arizona, and Creighton University, Medical Director of US
Oncology Research Gynecology program in Phoenix, Arizona.
The event will be webcast live and may be accessed by
visiting the "Events & Presentations" page within the Investors
section of the Agenus website at
www.agenusbio.com or by using the link below. A
replay of the webcast, as well as a copy of the slide
presentations that will be presented at the event, will be
available on the Agenus website following the event.
About Agenus
Agenus is a clinical-stage immuno-oncology company focused on the
discovery and development of therapies that engage the body's
immune system to fight cancer. The Company's vision is to expand
the patient populations benefiting from cancer immunotherapy by
pursuing combination approaches that leverage a broad repertoire of
antibody therapeutics, proprietary cancer vaccine platforms, and
adoptive cell therapies (through its AgenTus Therapeutics
subsidiary). The Company is equipped with a suite of antibody
discovery platforms and a state-of-the-art GMP manufacturing
facility with the capacity to support early phase clinical
programs. Agenus is headquartered in Lexington, MA. For more information, please
visit www.agenusbio.com and our twitter handle @agenus_bio.
Information that may be important to investors will be routinely
posted on our website and twitter.
Forward-Looking Statements
This press release contains
forward-looking statements that are made pursuant to the safe
harbor provisions of the federal securities laws, including
statements regarding the Company's plans to release clinical data
on balstilimab (anti-PD-1), zalifrelimab (anti-CTLA-4) and AGEN1181
at an upcoming investor day. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact:
Agenus Inc.
Regina Grebla, PhD
781-674-4495
Regina.Grebla@agenusbio.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/agenus-announces-positive-interim-data-from-balstilimab-and-zalifrelimab-clinical-trials-in-second-line-cervical-cancer-301008466.html
SOURCE Agenus Inc.